Aura GT
Fast, decisive, low-volume AAV characterization for gene therapy development workflows
Adeno-associated viruses (AAVs) have revolutionized gene therapy product development. With limited material available, allocating valuable samples for aggregate testing may have seemed impractical—until now.
Aura GT System is the first and only system designed to detect, count, and characterize AAV particles with just 5 µL. Combining backgrounded membrane imaging (BMI) with fluorescence membrane microscopy (FMM) dual-channel technology, confident decisions can be made earlier—one step closer to success.
Analyze small volumes. Only 5 µL of sample is needed, allowing particle characterization in early phase development.
Characterize and identify viral vectors. Aura GT System distinguishes between capsid and non-capsid aggregates and enables you to confirm whether DNA leakage is the root cause of aggregation straight from the box.
Gain deeper gene therapy understanding. Gain insight with Aura GT System’s duo of BMI and FMM, which distinguish and characterize different serotypes for aggregation and product features for deeper understanding of gene therapy – without tedious, labor-intensive assays.